Expand DARE Menu
DARE MENU

DARE Latest Press Releases

-- May 18, 2026 --

Dar Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies Globe Newswire 8:00 AM

-- May 14, 2026 --

Dar Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- May 12, 2026 --

Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive Globe Newswire 8:00 AM

-- May 7, 2026 --

Dar Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026 Globe Newswire 8:00 AM

-- March 26, 2026 --

Dar Bioscience Reports Full Year 2025 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- March 23, 2026 --

On National Viagra Day, Women Finally Claim Their Turn: Globe Newswire 8:00 AM

-- March 20, 2026 --

Dar Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 Globe Newswire 8:00 AM

-- March 16, 2026 --

Dar Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth Globe Newswire 8:00 AM

-- March 12, 2026 --

Dar Bioscience Participates in Virtual Investor "What This Means" Segment Globe Newswire 8:00 AM

-- February 23, 2026 --

Dar Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer Globe Newswire 8:00 AM

-- February 11, 2026 --

Telehealth Now Available for DARE to PLAY Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes